Galmed Pharmaceuticals to Acquire Colospan to Create a GI-Focused Platform Targeting a $6 Billion Market

Galmed Pharmaceuticals Ltd. has announced a definitive agreement to acquire Colospan Ltd., a commercial-stage medical device company, for $4.5 million. This transaction, which is expected to close in the second quarter of 2026, will allow Galmed to enhance its gastrointestinal (GI) platform by integrating Colospan's innovative technology aimed at addressing critical challenges in colorectal surgery.

Colospan is recognized for its flagship product, the CG-100 Intraluminal Bypass Device, which has received FDA Breakthrough Device Designation and is CE marked under the European Union's Medical Device Regulation. The device is designed to mitigate complications associated with anastomotic leaks, a significant concern in colorectal surgeries that can lead to increased morbidity and healthcare costs. With the CG-100 ready for commercial launch in the European Union and Israel, Galmed plans to invest an additional $6 million to facilitate its rollout, focusing initially on Germany, Austria, and Switzerland.

The acquisition aligns with Galmed's strategy to establish a diversified medtech and biopharmaceutical platform centered on gastrointestinal health. By combining its existing resources and clinical expertise with Colospan's proprietary technology, Galmed aims to accelerate the pivotal clinical program for the CG-100 device in the United States. This collaboration is expected to enhance the standard of care for patients undergoing colorectal resections, potentially reshaping treatment protocols and improving patient outcomes.

The medical devices sector, particularly in the gastrointestinal space, is experiencing significant growth driven by increasing awareness of colorectal health issues and the rising incidence of colorectal cancer. With approximately 1.9 million new cases diagnosed annually worldwide, the need for innovative solutions to manage surgical complications is more critical than ever. The CG-100 device addresses a pressing clinical need by offering a less invasive alternative to traditional methods, thereby improving patient quality of life and reducing the economic burden on healthcare systems.

In conclusion, the acquisition of Colospan Ltd. by Galmed Pharmaceuticals Ltd. represents a strategic move to strengthen its position in the medical devices market focused on gastrointestinal health. As the industry continues to evolve, this transaction underscores the importance of innovation in addressing unmet clinical needs and enhancing patient care. The successful integration of Colospan's technology within Galmed's framework could set a precedent for future collaborations in the sector, ultimately benefiting patients and healthcare providers alike.